These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 8784087)

  • 1. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
    Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin concentrations in the polycystic ovary syndrome.
    Mantzoros CS; Dunaif A; Flier JS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
    Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
    Azziz R; Ehrmann D; Legro RS; Whitcomb RW; Hanley R; Fereshetian AG; O'Keefe M; Ghazzi MN;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1626-32. PubMed ID: 11297595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
    Paradisi G; Steinberg HO; Shepard MK; Hook G; Baron AD
    J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
    Azziz R; Ehrmann DA; Legro RS; Fereshetian AG; O'Keefe M; Ghazzi MN;
    Fertil Steril; 2003 Apr; 79(4):932-7. PubMed ID: 12749433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.
    Thierry van Dessel HJ; Lee PD; Faessen G; Fauser BC; Giudice LC
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3030-5. PubMed ID: 10487660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Troglitazone for treatment of polycystic ovary syndrome].
    Sanaka M; Iwamoto Y
    Nihon Rinsho; 2000 Feb; 58(2):465-70. PubMed ID: 10707578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.
    Hasegawa I; Murakawa H; Suzuki M; Yamamoto Y; Kurabayashi T; Tanaka K
    Fertil Steril; 1999 Feb; 71(2):323-7. PubMed ID: 9988406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.
    Dereli D; Dereli T; Bayraktar F; Ozgen AG; Yilmaz C
    Endocr J; 2005 Jun; 52(3):299-308. PubMed ID: 16006724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
    Laboureau-Soares Barbosa S; Rodien P; Rohmer V
    Ann Endocrinol (Paris); 2002 Feb; 63(1):31-5. PubMed ID: 11937980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.